GTJA: Innovent Bio's Marziditide is expected to be approved by 25H1, maintaining a "shareholding" rating.

GTJA released a research report stating that Innovent Bio (01801) had intensive clinical data readings on its integrated pipeline and tumor pipeline. PD-1/IL2, CLND18.2ADC, and CLDN18.2/CD3 clinical data were excellent, and Marizomib is expected to be approved soon with enormous market potential. GTJA maintains a 'shareholding' rating, stating that it is optimistic about the company's integrated pipeline and Marizomib's layout in the IO+ADC tumor field, and its increase in domestic sales. GTJA's main viewpoints are as follows: Marizomib effectively reduces weight and decreases liver fat by more than 80%, indicating its potential entry into the MASH treatment market. According to GLOR.

新浪港股22:27 ET

Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2

Seeking Alpha20:30 ET

The Top Country With Most Scientists per Capita in the World

Yahoo FinanceJun 29 18:04 ET

Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report

Seeking AlphaJun 29 15:44 ET

Novo Nordisk Options Trading: A Deep Dive Into Market Sentiment

BenzingaJun 28 15:31 ET

Novo Nordisk Fully Valued Amid Limited Longer-Term Visibility -- Market Talk

WSJJun 28 08:01 ET